These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 31514949)
1. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study. Emanuelsson F; Nordestgaard BG; Tybjærg-Hansen A; Benn M J Am Coll Cardiol; 2019 Sep; 74(11):1465-1476. PubMed ID: 31514949 [TBL] [Abstract][Full Text] [Related]
2. Impact of Glucose Level on Micro- and Macrovascular Disease in the General Population: A Mendelian Randomization Study. Emanuelsson F; Marott S; Tybjærg-Hansen A; Nordestgaard BG; Benn M Diabetes Care; 2020 Apr; 43(4):894-902. PubMed ID: 32054721 [TBL] [Abstract][Full Text] [Related]
3. Investigating linear and nonlinear associations of LDL cholesterol with incident chronic kidney disease, atherosclerotic cardiovascular disease and all-cause mortality: A prospective and Mendelian randomization study. Wang Z; Xiao Y; Lu J; Zou C; Huang W; Zhang J; Liu S; Han L; Jiao F; Tian D; Jiang Y; Du X; Ma RCW; Jiang G Atherosclerosis; 2023 Dec; 387():117394. PubMed ID: 38029611 [TBL] [Abstract][Full Text] [Related]
4. HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study. Lanktree MB; Thériault S; Walsh M; Paré G Am J Kidney Dis; 2018 Feb; 71(2):166-172. PubMed ID: 28754456 [TBL] [Abstract][Full Text] [Related]
5. Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization. Zheng C; Lin Y; Jiang B; Zhu X; Lin Q; Luo W; Tang M; Xie L Front Endocrinol (Lausanne); 2022; 13():954453. PubMed ID: 36299452 [TBL] [Abstract][Full Text] [Related]
6. Causal effect between total cholesterol and HDL cholesterol as risk factors for chronic kidney disease: a mendelian randomization study. Miao L; Min Y; Qi B; Zhu CM; Chen JH; Deng GX; Wang Y; Li JF; Li RS BMC Nephrol; 2021 Jan; 22(1):35. PubMed ID: 33472594 [TBL] [Abstract][Full Text] [Related]
7. LDL-Cholesterol versus Glucose in Microvascular and Macrovascular Disease. Emanuelsson F; Benn M Clin Chem; 2021 Jan; 67(1):167-182. PubMed ID: 33221847 [TBL] [Abstract][Full Text] [Related]
8. Association of blood lipid profile with incident chronic kidney disease: A Mendelian randomization study. Zhang YB; Sheng LT; Wei W; Guo H; Yang H; Min X; Guo K; Yang K; Zhang X; He M; Wu T; Pan A Atherosclerosis; 2020 May; 300():19-25. PubMed ID: 32276134 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502 [TBL] [Abstract][Full Text] [Related]
10. A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes. Liu G; Shi M; Mosley JD; Weng C; Zhang Y; Lee MTM; Jarvik GP; Hakonarson H; Namjou-Khales B; Sleiman P; Luo Y; Mentch F; Denny JC; Linton MF; Wei WQ; Stein CM; Feng Q JAMA Netw Open; 2021 Jun; 4(6):e2112820. PubMed ID: 34097045 [TBL] [Abstract][Full Text] [Related]
12. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. ; Herrington WG; Emberson J; Mihaylova B; Blackwell L; Reith C; Solbu MD; Mark PB; Fellström B; Jardine AG; Wanner C; Holdaas H; Fulcher J; Haynes R; Landray MJ; Keech A; Simes J; Collins R; Baigent C Lancet Diabetes Endocrinol; 2016 Oct; 4(10):829-39. PubMed ID: 27477773 [TBL] [Abstract][Full Text] [Related]
13. Effects of ACLY Inhibition on Body Weight Distribution: A Drug Target Mendelian Randomization Study. Gill D; Dib MJ; Gill R; Bornstein SR; Burgess S; Birkenfeld AL Genes (Basel); 2024 Aug; 15(8):. PubMed ID: 39202419 [No Abstract] [Full Text] [Related]
14. Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study. Almramhi MM; Finan C; Storm CS; Schmidt AF; Kia DA; Coneys R; Chopade S; Hingorani AD; Wood NW Neurology; 2023 Oct; 101(17):e1729-e1740. PubMed ID: 37657941 [TBL] [Abstract][Full Text] [Related]
15. The Effect of Blood Lipids on the Left Ventricle: A Mendelian Randomization Study. Aung N; Sanghvi MM; Piechnik SK; Neubauer S; Munroe PB; Petersen SE J Am Coll Cardiol; 2020 Nov; 76(21):2477-2488. PubMed ID: 33213727 [TBL] [Abstract][Full Text] [Related]
16. Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease. Yang G; Mason AM; Gill D; Schooling CM; Burgess S Eur J Epidemiol; 2024 Aug; 39(8):857-867. PubMed ID: 39009924 [TBL] [Abstract][Full Text] [Related]
17. Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital. Sangsawang T; Sriwijitkamol A Vasc Health Risk Manag; 2015; 11():563-7. PubMed ID: 26604773 [TBL] [Abstract][Full Text] [Related]
18. 2017 Taiwan lipid guidelines for high risk patients. Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI; J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176 [TBL] [Abstract][Full Text] [Related]
19. Association of lipids and lipid-lowering drugs with peripheral arterial disease: A Mendelian randomization study. Tao M; Zhang Y; Li Q; Feng X; Ping C J Clin Lipidol; 2024 Jul; ():. PubMed ID: 39304430 [TBL] [Abstract][Full Text] [Related]
20. The Causal Effect of Systolic Blood Pressure Lowering on Vascular Outcomes in Diabetes: A Mendelian Randomization Study. Hou T; Li M; Lin H; Zhao Z; Lu J; Wang T; Xu Y; Wang W; Bi Y; Ning G; Xu M J Clin Endocrinol Metab; 2022 Aug; 107(9):2616-2625. PubMed ID: 35703944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]